[1] Ok. F. Macsween and D. H. Crawford, “Epstein-Barr virus-recent advances,” Lancet Infect. Dis., vol. 3, no. 3, pp. 131–140, 2003.
[2] A. Fugl and C. L. Andersen, “Epstein-Barr virus and its affiliation with illness – a overview of relevance to normal apply,” BMC Fam. Pract., vol. 20, no. 1, 2019.
[3] G. Niedobitek, N. Meru, and H. J. Delecluse, “Epstein-Barr virus an infection and human malignancies,” Int. J. Exp. Pathol., vol. 82, no. 3, pp. 149–170, 2001.
[4] CDC, “About Mono (Infectious Mononucleosis),” Facilities for Illness Management and Prevention (CDC), 23-Jan-2023. [Online]. Accessible: https://www.cdc.gov/epstein-barr/about-mono.html
[5] M. De Paor, Ok. O’Brien, T. Fahey, and S. M. Smith, “Antiviral brokers for infectious mononucleosis (glandular fever),” Cochrane Database Syst. Rev., vol. 12, no. 12, p. CD011487, 2016.
[6] S. Soran, “The affiliation of Epstein-Barr virus an infection with progress of most cancers and immune defects,” Gov.tr, 2017. [Online]. Accessible: https://acikbilim.yok.gov.tr/bitstream/deal with/20.500.12812/70031/yokAcikBilim_10148063.pdf?sequence=-1
[7] E. G. Donald and B. M. Gregoire, “The Darkish Facet of MONO,” Tutorial Journal of Pediatrics and Neonatology, vol. 5, no. 3, 2017.
[8] M. Saljoughian and PhD Division of Pharmacy Alta Bates Summit Medical Middle Berkeley, “Diagnosing and treating mononucleosis,” Uspharmacist.com, 19-Could-2017. [Online]. Accessible: https://www.uspharmacist.com/article/diagnosing-and-treating-mononucleosis?utm_source=TrendMD&utm_medium=cpc&utm_campaign=US_Pharmacist_TrendMD_1
[9] J. I. Cohen, “Vaccine improvement for Epstein-Barr virus,” Adv. Exp. Med. Biol., vol. 1045, pp. 477–493, 2018.
[10] M. Liu et al., “Epidemiological traits and illness burden of infectious mononucleosis in hospitalized kids in China: A nationwide retrospective research,” Virol. Sin., vol. 37, no. 5, pp. 637–645, 2022.
[11] J. I. Cohen, “Epstein-barr virus vaccines,” Clin. Transl. Immunology, vol. 4, no. 1, p. e32, 2015.
[12] CDC, “About Epstein-Barr virus (EBV),” Facilities for Illness Management and Prevention (CDC), 03-Oct-2022. [Online]. Accessible: https://www.cdc.gov/epstein-barr/about-ebv.html
[13] M. H. Ebell, “Epstein-Barr virus infectious mononucleosis,” Umich.edu. [Online]. Accessible: https://www.med.umich.edu/digitallab/m2pathlabs/hemepath/PDFpercent20files/2004percent20concisepercent20reviewpercent20mononucleosis.pdf
[14] E. Visser, D. Milne, I. Collacott, D. McLernon, C. Counsell, and M. Vickers, “The epidemiology of infectious mononucleosis in Northern Scotland: a reducing incidence and winter peak,” BMC Infect. Dis., vol. 14, no. 1, p. 151, 2014.
[15] Ok. Bjornevik et al., “Longitudinal evaluation reveals excessive prevalence of Epstein-Barr virus related to a number of sclerosis,” Science, vol. 375, no. 6578, pp. 296–301, 2022.
[16] “NIH launches medical trial of Epstein-Barr virus vaccine,” Nationwide Institutes of Well being (NIH), 06-Could-2022. [Online]. Accessible: https://www.nih.gov/news-events/news-releases/nih-launches-clinical-trial-epstein-barr-virus-vaccine
[17] J. B. Harford, “Viral infections and human cancers: the legacy of Denis Burkitt: Overview,” Br. J. Haematol., vol. 156, no. 6, pp. 709–718, 2012.
